JP2020002171A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020002171A5 JP2020002171A5 JP2019166361A JP2019166361A JP2020002171A5 JP 2020002171 A5 JP2020002171 A5 JP 2020002171A5 JP 2019166361 A JP2019166361 A JP 2019166361A JP 2019166361 A JP2019166361 A JP 2019166361A JP 2020002171 A5 JP2020002171 A5 JP 2020002171A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- pharmaceutical composition
- composition according
- administered
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 31
- 206010019860 Hereditary angioedema Diseases 0.000 claims 13
- 108090000113 Plasma Kallikrein Proteins 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 11
- 102000003827 Plasma Kallikrein Human genes 0.000 claims 8
- 230000036470 plasma concentration Effects 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022168140A JP2023015087A (ja) | 2014-01-21 | 2022-10-20 | 遺伝性血管浮腫の治療における血漿カリクレイン結合タンパク質およびその使用 |
| JP2024151126A JP2024170495A (ja) | 2014-01-21 | 2024-09-03 | 遺伝性血管浮腫の治療における血漿カリクレイン結合タンパク質およびその使用 |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461929716P | 2014-01-21 | 2014-01-21 | |
| US61/929,716 | 2014-01-21 | ||
| US201461944361P | 2014-02-25 | 2014-02-25 | |
| US61/944,361 | 2014-02-25 | ||
| US201462021397P | 2014-07-07 | 2014-07-07 | |
| US62/021,397 | 2014-07-07 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016547570A Division JP6845012B2 (ja) | 2014-01-21 | 2015-01-21 | 遺伝性血管浮腫の治療における血漿カリクレイン結合タンパク質およびその使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022168140A Division JP2023015087A (ja) | 2014-01-21 | 2022-10-20 | 遺伝性血管浮腫の治療における血漿カリクレイン結合タンパク質およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020002171A JP2020002171A (ja) | 2020-01-09 |
| JP2020002171A5 true JP2020002171A5 (enExample) | 2020-02-20 |
| JP7164502B2 JP7164502B2 (ja) | 2022-11-01 |
Family
ID=53681890
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016547570A Active JP6845012B2 (ja) | 2014-01-21 | 2015-01-21 | 遺伝性血管浮腫の治療における血漿カリクレイン結合タンパク質およびその使用 |
| JP2019166361A Active JP7164502B2 (ja) | 2014-01-21 | 2019-09-12 | 遺伝性血管浮腫の治療における血漿カリクレイン結合タンパク質およびその使用 |
| JP2022168140A Pending JP2023015087A (ja) | 2014-01-21 | 2022-10-20 | 遺伝性血管浮腫の治療における血漿カリクレイン結合タンパク質およびその使用 |
| JP2024151126A Pending JP2024170495A (ja) | 2014-01-21 | 2024-09-03 | 遺伝性血管浮腫の治療における血漿カリクレイン結合タンパク質およびその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016547570A Active JP6845012B2 (ja) | 2014-01-21 | 2015-01-21 | 遺伝性血管浮腫の治療における血漿カリクレイン結合タンパク質およびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022168140A Pending JP2023015087A (ja) | 2014-01-21 | 2022-10-20 | 遺伝性血管浮腫の治療における血漿カリクレイン結合タンパク質およびその使用 |
| JP2024151126A Pending JP2024170495A (ja) | 2014-01-21 | 2024-09-03 | 遺伝性血管浮腫の治療における血漿カリクレイン結合タンパク質およびその使用 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11084884B2 (enExample) |
| EP (2) | EP3848057B1 (enExample) |
| JP (4) | JP6845012B2 (enExample) |
| KR (4) | KR20240049627A (enExample) |
| CN (2) | CN116585468A (enExample) |
| AU (3) | AU2015209481C1 (enExample) |
| BR (1) | BR112016016916B1 (enExample) |
| CA (1) | CA2937329C (enExample) |
| DK (1) | DK3096798T3 (enExample) |
| EA (1) | EA038532B1 (enExample) |
| ES (1) | ES2856076T3 (enExample) |
| IL (3) | IL246864B (enExample) |
| MX (2) | MX387753B (enExample) |
| NZ (2) | NZ761006A (enExample) |
| PL (1) | PL3096798T3 (enExample) |
| PT (1) | PT3096798T (enExample) |
| WO (1) | WO2015112578A1 (enExample) |
| ZA (2) | ZA201605342B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20220107T1 (hr) | 2010-01-06 | 2022-04-15 | Takeda Pharmaceutical Company Limited | Proteini koji vežu kalikrein plazme |
| CN105713092B (zh) * | 2011-01-06 | 2019-09-10 | 戴埃克斯有限公司 | 血浆前激肽释放酶结合蛋白 |
| ES2692408T3 (es) | 2013-01-20 | 2018-12-03 | Dyax Corp. | Evaluación y tratamiento de trastornos mediados por bradiquinina |
| IL292121B2 (en) | 2013-03-15 | 2024-02-01 | Takeda Pharmaceuticals Co | Anti-plasma kallikrein antibodies |
| IL289514B2 (en) | 2013-10-21 | 2024-01-01 | Takeda Pharmaceuticals Co | Assays for determining plasma kallikrein system biomarkers |
| ES2873204T3 (es) | 2013-10-21 | 2021-11-03 | Takeda Pharmaceuticals Co | Diagnóstico y tratamiento de enfermedades autoinmunes |
| PT3096798T (pt) * | 2014-01-21 | 2021-02-25 | Dyax Corp | Proteínas de ligação à calicreína plasmática e seus usos no tratamento de angioedema hereditário |
| IL247942B (en) | 2014-03-27 | 2022-09-01 | Dyax Corp | Compositions and methods for drops in macular edema as a result of diabetes |
| CN107614532A (zh) * | 2015-03-30 | 2018-01-19 | 戴埃克斯有限公司 | 血浆激肽释放酶抑制剂及其预防遗传性血管性水肿发作的用途 |
| WO2017035263A1 (en) * | 2015-08-24 | 2017-03-02 | Biocryst Pharmaceuticals, Inc. | Compositions comprising a plasma kallikrein inhibitor |
| MX2018004763A (es) * | 2015-10-19 | 2018-09-06 | Dyax Corp | Inmunoensayo para detectar quininogeno escindido de alto peso molecular. |
| KR20250139401A (ko) * | 2015-12-11 | 2025-09-23 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 저해제 및 유전성 혈관부종 발작을 치료하기 위한 이의 용도 |
| EP3513196A1 (en) * | 2016-09-16 | 2019-07-24 | Dyax Corp. | Protein biomarkers for diseases associated with the contact activation system |
| CN117187377A (zh) | 2016-09-16 | 2023-12-08 | 武田药品工业株式会社 | 用于遗传性血管性水肿的rna生物标记 |
| WO2019079496A2 (en) * | 2017-10-18 | 2019-04-25 | Regenxbio, Inc. | FULLY HUMAN ANTIBODY-BASED THERAPEUTIC AGENTS HAVING POST-TRANSLATION MODIFICATION |
| KR102756073B1 (ko) | 2017-12-01 | 2025-01-20 | 쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드 | 이중-가닥 올리고뉴클레오티드, 조성물 및 이중-가닥 올리고뉴클레오티드를 포함하는 접합체, 그의 제조 방법 및 그의 용도 |
| WO2019105419A1 (zh) | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| JP7261494B2 (ja) | 2017-12-01 | 2023-04-20 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用 |
| WO2019105435A1 (zh) | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| US12083142B2 (en) | 2017-12-01 | 2024-09-10 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof |
| HRP20250408T1 (hr) | 2017-12-29 | 2025-06-06 | Suzhou Ribo Life Science Co., Ltd. | Kojugati i njihova priprema i uporaba |
| US11918600B2 (en) | 2018-08-21 | 2024-03-05 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof |
| CN111655297A (zh) | 2018-09-30 | 2020-09-11 | 苏州瑞博生物技术有限公司 | 一种siRNA缀合物及其制备方法和用途 |
| US12163956B2 (en) | 2019-02-21 | 2024-12-10 | Takeda Pharmaceutical Company Limited | Lateral flow immunoassay for measuring functional C1-esterase inhibitor (C1-INH) in plasma samples |
| AU2020237259A1 (en) * | 2019-03-14 | 2021-10-14 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
| JP7614650B2 (ja) * | 2019-05-24 | 2025-01-16 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、薬物組成物及び複合体並びに調製方法と使用 |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| US5444156A (en) * | 1985-07-12 | 1995-08-22 | Temple University-Of The Commonwealth System Of Higher Education | Monoclonal antibodies to human plasma prekallikrein |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| EP0296171A4 (en) | 1986-03-03 | 1989-11-07 | Brigham & Womens Hospital | ASSESSMENT PROCEDURE FOR NEPHROTOXICITY. |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US5045452A (en) | 1988-09-02 | 1991-09-03 | Brigham And Women's Hospital | Method for evaluating nephrotoxicity |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
| CA2180950C (en) | 1994-01-11 | 2005-03-29 | William Markland | Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| DE19632772A1 (de) | 1996-08-14 | 1998-02-19 | Basf Ag | Neue Benzamidine |
| US5840871A (en) | 1997-01-29 | 1998-11-24 | Incyte Pharmaceuticals, Inc. | Prostate-associated kallikrein |
| US6913900B2 (en) | 2001-08-29 | 2005-07-05 | Nippon Zoki Pharmaceutical Co., Ltd. | Plasma prekallikrein activation and kallikrein production assay |
| EP1441589B1 (en) | 2001-11-08 | 2012-05-09 | Abbott Biotherapeutics Corp. | Stable liquid pharmaceutical formulation of igg antibodies |
| ES2528254T3 (es) | 2002-06-07 | 2015-02-05 | Dyax Corp. | Polipéptidos de dominio Kunitz modificado y su uso para reducir la isquemia o el inicio de una respuesta inflamatoria sistémica asociada con un procedimiento quirúrgico |
| US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| EP1674480A4 (en) | 2003-09-04 | 2007-06-20 | Riken | ANTIBODY RECOGNIZING THE REGIONAL SECTION CONTROLLING TGF-BETA ACTIVATION |
| US20070253949A1 (en) | 2004-02-03 | 2007-11-01 | Stefan Golz | Diagnostics and Therapeutics for Diseases Associated with Plasma Kallikrein (KLKB1) |
| US7329737B2 (en) | 2004-08-03 | 2008-02-12 | Dyax Corp. | Antibodies that bind hK-1 |
| US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
| SI2374472T1 (sl) | 2006-03-16 | 2018-11-30 | Dyax Corp., | Sestavki in postopki za zdravljenje oftalmoloških motenj |
| EP2051707B1 (en) | 2006-07-31 | 2013-07-17 | Activesite Pharmaceuticals, Inc. | Inhibitors of plasma kallikrein |
| CN101495468A (zh) * | 2006-07-31 | 2009-07-29 | 艾克提弗赛特制药股份有限公司 | 血浆激肽释放酶抑制剂 |
| KR100846354B1 (ko) | 2007-03-21 | 2008-07-15 | (주) 프로탄바이오 | 혈청 당단백질부터 분리한 폐암 진단용 마커 |
| US8501695B2 (en) * | 2007-07-20 | 2013-08-06 | Diamedica, Inc. | Tissue kallikrein for the treatment of diseases associated with amyloid protein |
| CA2695012A1 (en) | 2007-08-23 | 2009-02-26 | Genzyme Corporation | Treatment with kallikrein inhibitors |
| AU2009266856A1 (en) | 2008-07-02 | 2010-01-07 | Emergent Product Development Seattle, Llc | IL6 immunotherapeutics |
| EP2385843A4 (en) | 2009-01-06 | 2013-02-27 | Dyax Corp | TREATMENT OF MUZOSITIS WITH CALLICINE INHIBITORS |
| CN101928346B (zh) | 2009-07-31 | 2013-01-16 | 华中科技大学同济医学院附属同济医院 | 一种抗人组织激肽释放酶单克隆抗体及其制备 |
| HRP20220107T1 (hr) | 2010-01-06 | 2022-04-15 | Takeda Pharmaceutical Company Limited | Proteini koji vežu kalikrein plazme |
| CN105713092B (zh) | 2011-01-06 | 2019-09-10 | 戴埃克斯有限公司 | 血浆前激肽释放酶结合蛋白 |
| WO2012142308A1 (en) | 2011-04-13 | 2012-10-18 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
| KR102136208B1 (ko) | 2011-05-02 | 2020-07-21 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 항-α4β7 항체에 대한 제형 |
| WO2013123114A2 (en) | 2012-02-16 | 2013-08-22 | Santarus, Inc. | Antibody formulations |
| US9216219B2 (en) | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
| KR102419640B1 (ko) | 2013-01-20 | 2022-07-12 | 다케다 파머수티컬 컴패니 리미티드 | pKal 매개 장애의 평가, 검정 및 치료 |
| ES2692408T3 (es) | 2013-01-20 | 2018-12-03 | Dyax Corp. | Evaluación y tratamiento de trastornos mediados por bradiquinina |
| IL292121B2 (en) | 2013-03-15 | 2024-02-01 | Takeda Pharmaceuticals Co | Anti-plasma kallikrein antibodies |
| KR20140119396A (ko) | 2013-03-29 | 2014-10-10 | 삼성전자주식회사 | 단백질 약물의 액상 제형 |
| IL289514B2 (en) | 2013-10-21 | 2024-01-01 | Takeda Pharmaceuticals Co | Assays for determining plasma kallikrein system biomarkers |
| PT3096798T (pt) * | 2014-01-21 | 2021-02-25 | Dyax Corp | Proteínas de ligação à calicreína plasmática e seus usos no tratamento de angioedema hereditário |
| IL247942B (en) | 2014-03-27 | 2022-09-01 | Dyax Corp | Compositions and methods for drops in macular edema as a result of diabetes |
| CN107614532A (zh) | 2015-03-30 | 2018-01-19 | 戴埃克斯有限公司 | 血浆激肽释放酶抑制剂及其预防遗传性血管性水肿发作的用途 |
| KR20250139401A (ko) | 2015-12-11 | 2025-09-23 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 저해제 및 유전성 혈관부종 발작을 치료하기 위한 이의 용도 |
| CN109716137B (zh) * | 2016-09-16 | 2023-07-21 | 武田药品工业株式会社 | 用于与接触活化系统相关的疾病的代谢产物生物标记 |
| EP3678553B1 (en) | 2017-09-05 | 2024-05-22 | Sanolla Ltd | Diagnosis of pathologies using infrasonic signatures |
| JP7585193B2 (ja) | 2018-08-30 | 2024-11-18 | 武田薬品工業株式会社 | 血漿カリクレイン阻害剤及び遺伝性血管浮腫発作を処置するためのその使用 |
| AU2020237259A1 (en) | 2019-03-14 | 2021-10-14 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
| CA3167336A1 (en) | 2020-01-13 | 2021-07-22 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack |
-
2015
- 2015-01-21 PT PT157407743T patent/PT3096798T/pt unknown
- 2015-01-21 EP EP20209536.0A patent/EP3848057B1/en active Active
- 2015-01-21 CN CN202310760869.5A patent/CN116585468A/zh active Pending
- 2015-01-21 CA CA2937329A patent/CA2937329C/en active Active
- 2015-01-21 KR KR1020247010766A patent/KR20240049627A/ko active Pending
- 2015-01-21 KR KR1020167022785A patent/KR102424183B1/ko active Active
- 2015-01-21 CN CN201580010172.XA patent/CN106132442B/zh active Active
- 2015-01-21 AU AU2015209481A patent/AU2015209481C1/en active Active
- 2015-01-21 ES ES15740774T patent/ES2856076T3/es active Active
- 2015-01-21 NZ NZ761006A patent/NZ761006A/en unknown
- 2015-01-21 KR KR1020247006911A patent/KR20240033156A/ko active Pending
- 2015-01-21 JP JP2016547570A patent/JP6845012B2/ja active Active
- 2015-01-21 BR BR112016016916-6A patent/BR112016016916B1/pt active IP Right Grant
- 2015-01-21 MX MX2016009428A patent/MX387753B/es unknown
- 2015-01-21 US US15/113,297 patent/US11084884B2/en active Active
- 2015-01-21 PL PL15740774T patent/PL3096798T3/pl unknown
- 2015-01-21 DK DK15740774.3T patent/DK3096798T3/da active
- 2015-01-21 EA EA201691470A patent/EA038532B1/ru unknown
- 2015-01-21 KR KR1020227025028A patent/KR20220107077A/ko not_active Ceased
- 2015-01-21 WO PCT/US2015/012212 patent/WO2015112578A1/en not_active Ceased
- 2015-01-21 EP EP15740774.3A patent/EP3096798B1/en active Active
- 2015-01-21 NZ NZ723369A patent/NZ723369A/en unknown
-
2016
- 2016-07-20 IL IL246864A patent/IL246864B/en active IP Right Grant
- 2016-07-20 MX MX2021013665A patent/MX2021013665A/es unknown
- 2016-08-02 ZA ZA201605342A patent/ZA201605342B/en unknown
-
2018
- 2018-12-12 IL IL263669A patent/IL263669B/en active IP Right Grant
-
2019
- 2019-09-12 JP JP2019166361A patent/JP7164502B2/ja active Active
-
2020
- 2020-07-28 ZA ZA2020/04653A patent/ZA202004653B/en unknown
- 2020-09-02 US US17/010,354 patent/US12384854B2/en active Active
- 2020-09-28 AU AU2020244370A patent/AU2020244370B2/en active Active
- 2020-10-14 IL IL278062A patent/IL278062B/en unknown
-
2022
- 2022-10-20 JP JP2022168140A patent/JP2023015087A/ja active Pending
-
2024
- 2024-05-23 AU AU2024203436A patent/AU2024203436A1/en active Pending
- 2024-09-03 JP JP2024151126A patent/JP2024170495A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020002171A5 (enExample) | ||
| JP2017503820A5 (enExample) | ||
| JP2017507139A5 (enExample) | ||
| JP2017160208A5 (enExample) | ||
| JP2022033868A5 (enExample) | ||
| JP2017506626A5 (enExample) | ||
| RU2016136364A (ru) | Способы лечения или предупреждения астмы посредством введения антагониста il-4r | |
| JP2019523295A5 (enExample) | ||
| JP2003531129A5 (enExample) | ||
| JP2006522830A5 (enExample) | ||
| RU2005127429A (ru) | Активная иммунизация для создания антител к растворимому а-бета | |
| JP2017537105A5 (enExample) | ||
| JP2019501886A5 (enExample) | ||
| JP2013521303A5 (enExample) | ||
| JP2014114288A5 (enExample) | ||
| JP2013533858A5 (enExample) | ||
| JP2016529255A5 (enExample) | ||
| JP2008538564A5 (enExample) | ||
| JP2016538277A5 (enExample) | ||
| JP2018514510A5 (enExample) | ||
| JP2018523684A5 (enExample) | ||
| JP2019528285A5 (enExample) | ||
| JP2020504110A5 (enExample) | ||
| JP2019512472A5 (enExample) | ||
| JP2018529661A5 (enExample) |